Tocagen’s $98 Million Initial Public Offering

Cooley advised Tocagen on its $97.8 million initial public offering of 9,775,000 shares of common stock.

San Diego-based Tocagen, which trades on The NASDAQ Global Select Market as “TOCA,” is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer.

Cooley has advised with a team led by Fred Muto (Picture).

Involved fees earner: Fred Muto – Cooley LLP; Ken Rollins – Cooley LLP; Karen Deschaine – Cooley LLP; Wade Andrews – Cooley LLP; Matt Robbins – Cooley LLP; Brandon Seal – Cooley LLP; Natasha Leskovsek – Cooley LLP; Wendy Goldstein – Cooley LLP; Phil Mitchell – Cooley LLP; Megan Arthur Schilling – Cooley LLP; Dani Nazemian – Cooley LLP; Susan Cooper Philpot – Cooley LLP;

Law Firms: Cooley LLP;

Clients: Tocagen Inc.;


Author: Ambrogio Visconti